Actuate Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Voss Capital and affiliated entities have filed an amended Schedule 13G, reporting beneficial ownership of 7.7% of Actuate Therapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
Voss Capital, LP and affiliated entities have reported a 5.3% beneficial ownership stake in Actuate Therapeutics, Inc. common stock.